g


Register Interest

Chimeric Therapeutics Ltd

CHM’s strategy is to develop a highly prospective portfolio of clinical-stage cell therapy products including CAR T and NK therapies, developed at the world’s leading medical institutions, and to drive these drugs successfully through clinical development for the benefit of cancer patients globally.